Lorlatinib, with dual ALK and ROS1 inhibition, gained FDA-approval for first line treatment of ALK-rearranged NSCLC following the interim results of the phase III CROWN study, confirming an intracranial ORR of 82% (95% CI: 57–96) among lorlatinib-treated TKI-naïve patients with measurable brain metastases [84]. This evidence concerns the gene ALK and non-small cell lung carcinoma.